Genentech · 15 hours ago
2026 Summer Intern - Research Oncology
South San Francisco, CA
Internship
Onsite
Intern
$33/hr - $46/hr
Start in 2026 SummerGenentech is seeking a highly motivated Summer Intern in Immuno-Oncology to join their research team focused on T cell biology and next-generation immunotherapies. This internship offers hands-on experience in translational research aimed at harnessing the immune system to treat cancer, working closely with experienced scientists in a collaborative environment.
BiotechnologyLife ScienceManufacturing
Responsibilities
Collaborate work with a team of scientists to design, execute and interpret experiments
Compile and present work to the greater scientific community at Genentech
Potential to participate in business critical research
Qualification
Required
Must have attained a Bachelor's Degree
Must be pursuing a Master's Degree (enrolled student)
Must have attained a Master's Degree
Must be pursuing a PhD (enrolled student)
Required Majors: Biology, Cancer Immunology, Immunology, Oncology or related fields
Experience with flow cytometry, tissue processing and cell culture
Preferred
Excellent communication, collaboration, and interpersonal skills
Complements our culture and the standards that guide our daily behavior & decisions: Integrity, Courage, and Passion
Experience with viral work
Technical expertise with genome engineering (CRISPR/Cas9) and molecular biology techniques (DNA, RNA, PCR, Western Blotting) is desirable
Some knowledge of R is preferred
Benefits
Paid holiday time off benefits
Company
Genentech
Genentech is a biotechnology research company that specializes in genetic testing and personalized medicines.
Founded in 1976
10001+ employees
H1B Sponsorship
Genentech has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (167)
2024 (148)
2023 (150)
2022 (178)
2021 (121)
2020 (158)
Funding
Current Stage
Public CompanyTotal Funding
unknown2009-03-26Acquired
1999-07-20IPO
1976-01-01Series Unknown
Leadership Team
Ashley Magargee
Chief Executive Officer
Michael Laird
Vice President, Global MSAT Drug Substance Biologics Technology and Commercial Products Support
Recent News
Genetic Engineering News
2026-02-05
Bizjournals.com Feed (2025-11-12 15:43:17)
2026-02-05
BioWorld Financial Watch
2026-02-04
Company data provided by crunchbase